Cargando…
Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi
BACKGROUND: Malaria is the leading cause of morbidity and mortality in post-conflict Burundi. To counter the increasing challenge of anti-malarial drug resistance and improve highly effective treatment Burundi adopted artesunate-amodiaquine (AS-AQ) as first-line treatment for uncomplicated Plasmodiu...
Autores principales: | Amuasi, John H, Diap, Graciela, Blay-Nguah, Samuel, Boakye, Isaac, Karikari, Patrick E, Dismas, Baza, Karenzo, Jeanne, Nsabiyumva, Lievin, Louie, Karly S, Kiechel, Jean-René |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3050774/ https://www.ncbi.nlm.nih.gov/pubmed/21310057 http://dx.doi.org/10.1186/1475-2875-10-34 |
Ejemplares similares
-
Access to Artemisinin-Combination Therapy (ACT) and other Anti-Malarials: National Policy and Markets in Sierra Leone
por: Amuasi, John H., et al.
Publicado: (2012) -
The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study
por: Wells, Susan, et al.
Publicado: (2013) -
Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine
por: Ogutu, Bernhards, et al.
Publicado: (2014) -
The affordable medicines facility - malaria in Ghana: baseline and endline survey findings
por: Amuasi, John H, et al.
Publicado: (2012) -
Population pharmacokinetics of artesunate and amodiaquine in African children
por: Stepniewska, Kasia, et al.
Publicado: (2009)